Subscribe to the daily news Sign in
En
Bespak and Orbia Partner to Develop Climate-Friendly Inhalers
14 November 2024

Bespak and Orbia Partner to Develop Climate-Friendly Inhalers

Bespak, a leading contract development and manufacturing organization (CDMO) in inhalation therapies, has partnered with Orbia Advance Corporation’s (BMV: ORBIA*) Fluor & Energy Materials division, known for its expertise in fluoroproducts and sustainable propellant technology, to fast-track the commercialization of low global warming potential (GWP) inhalers. This collaboration leverages Orbia’s Zephex 152a propellant at Bespak’s Holmes Chapel facility in the UK.

Bespak has taken considerable steps to support the pMDI industry’s shift from traditional propellants to environmentally responsible alternatives, showcasing the viability of pMDI formulations with low GWP propellants. The company’s comprehensive capabilities - from GLP lab-scale testing and product development to clinical and commercial-scale manufacturing - position it as a pivotal player in this transition. Bespak recently expanded its services with the availability of clinical supply solutions using HFA-152a, in partnership with H&T Presspart, and invested in a new high-speed filling line at Holmes Chapel to handle commercial production with this propellant.

Orbia Fluor & Energy Materials’ expertise in propellant innovation, combined with Bespak’s leadership in pMDI components, aims to accelerate reformulation and commercial production of low GWP inhalers. Their collaborative focus in the North West of England, an area renowned for its pMDI expertise, and additional support from Bespak’s King’s Lynn team, promises efficiency and agility in bringing new formulations to market.

Chris Hirst, CEO of Bespak, affirmed their dedication to enabling customers to adapt to evolving global regulations with sustainable inhaler options, stating: “Our goal is to transition as many formulations as possible, preserving patient access to pMDIs. We look forward to advancing with Orbia Fluor & Energy Materials at our Holmes Chapel site.”

Markus Laubscher, General Manager of Orbia Fluor & Energy Materials Pharma Business Unit, highlighted the partnership’s significance: “This collaboration is a critical step in launching pMDIs with our Zephex 152a propellant. Bespak’s expertise from valves and actuators to manufacturing scalability makes them an ideal partner in this industry-shaping initiative.”

Share
Get the daily refrigeration briefing
Trusted by 3,000+ refrigeration professionals worldwide
By subscribing, you create a free Refindustry account and agree to our Terms of Service and Privacy Policy.
No spam. Only industry-relevant news.
Unsubscribe anytime.

Related news

German VDKF Calls for HVACR Survey Participation
The Verband Deutscher Kälte-Klima-Fachbetriebe (VDKF e.V.) is conducting its Kälte-Klima-Konjunkturumfrage again this year to assess the current and expected market situation in Germany’s refri...
01 May 2026
FETA urges balanced UK PFAS rules after EAC report
FETA has responded to the UK Environmental Audit Committee’s report on the risks posed by per- and polyfluoroalk
29 Apr 2026
EU Safety Rules Trump F-Gas Certification for Natural Refrigerant Work
The European Commission has confirmed that occupational safety and health directives fully apply to technicians working with natural refrigerants and are not replaced by F-gas certification und...
14 Apr 2026
Australia seeks industry feedback on refrigerant reclaim scheme
Refrigerant Reclaim Australia is seeking feedback from holders of Arctick permits as part of a review of Australia’s refrigerant recovery stewardship scheme. The survey asks permit hol...
01 May 2026
EIA Bulletin Highlights U.S. Illegal HFC Import Cases
The Environmental Investigation Agency’s seventh Illegal Trade Bulletin highlights two U.S. enforcement cases involving illegal refrigerant trade under the American Innovation and Manufacturing Act...
28 Apr 2026
Chemours posts 2025 loss; Opteon refrigerants sales rise 56%
The Chemours Company reported full-year 2025 net sales of $5.8 billion, flat versus 2024, and a net loss attributable to Chemours of $386 million ($2.57 per diluted share), compared with net income...
23 Feb 2026